Quest Diagnostics Newsroom - News Releases
Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers
News Releases - Quest Diagnostics Newsroom
Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers
Quest Diagnostics Newsroom - Newsroom
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
Quest Diagnostics Newsroom - About Quest®
With consumer led testing from Quest, consumers can access tests directly, empowering people to take control of their health by allowing them to purchase the same quality laboratory tests doctors and hospitals order at their convenience, without visiting a doctor first.
Quest Diagnostics and NewYork-Presbyterian Complete …
Apr 17, 2023 · Quest provides a complete portfolio of services to empower health systems and hospitals to improve the quality, innovation and insights of their diagnostic laboratory services, elevate the patient experience and lower costs for more accessible—and affordable—care.
Quest Diagnostics Newsroom - News Releases
Recent News Highlights. Corporate News. Haystack Oncology will join Quest Diagnostics through acquisition, adding minimal residual disease testing for patients treated for cancer to Quest’s oncology services portfolio. Quest reported first-quarter 2023 revenues of $2.33 billion and updated guidance for the full year.
Quest Diagnostics Newsroom - News Releases
Jan 5, 2023 · Quest Diagnostics Health Trends™ Study with CDC Reveals Pandemic’s Impact on Hepatitis C Testing and Treatment; New K-12 School COVID-19 Test Collaborations and $0 Out-Of-Pocket COVID-19 Test Option Help Foster Safer Environments
News Releases - Quest Diagnostics Newsroom
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share,...
Quest Diagnostics Newsroom - News Releases
Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
Quest Diagnostics Newsroom - News Releases
The ELF™ Test is the first and only prognostic blood test granted De Novo marketing authorization to assess disease progression in NASH patients. The ELF Test is now available nationwide through collaborations with Labcorp and Quest Diagnostics.
Quest Diagnostics Stock - On A Quest For Growth - Seeking Alpha
SponsoredSeeking Alpha Has the Analysis You Need to Make Smarter Investing Decisions. Take advantage of potential growth with timely investment data and analysis.Types: Market News, Top Stocks, Stock Ideas, Investment Strategies, Alpha Picks
